Suppr超能文献

中年 Fontan 患者的临床特征和结局。

Clinical characteristics and outcomes in middle-aged Fontan patients.

机构信息

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55905, United States of America.

Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55905, United States of America.

出版信息

Int J Cardiol. 2025 Jan 1;418:132658. doi: 10.1016/j.ijcard.2024.132658. Epub 2024 Oct 18.

Abstract

BACKGROUND

Middle-aged Fontan patients are underrepresented in contemporary studies. The purpose of this study was to describe the clinical characteristics and outcomes in middle-aged patients with Fontan palliation.

METHODS

All adults with Fontan palliation were divided into 'middle-aged' group (>40 years of age at baseline encounter), and 'young adult' group. Clinical characteristics were assessed across multiple domains (atrial arrhythmias, heart failure, and hepatorenal function). Clinical outcomes were assessed as composite outcome of death/heart transplant.

RESULTS

Of 455 adults (median age 26 years), 63 (14 %) were middle-aged adults while 392 (86 %) were young adults. Compared to the young adult group, the middle-aged group had a higher prevalence of atrial arrhythmias, greater neurohormonal activation, and worse hepatorenal function. Of 63 patients in the middle-aged group, 26 (41 %) patients died, and 4 (6 %) patients underwent heart transplant. The middle-aged group had a higher 5-year cumulative incidence of death/transplant (45 % versus 21 %, p < 0.001), and 10-year cumulative incidence of death/transplant (64 % versus 29 %, p < 0.001) compared to the young adult group. Higher pulmonary artery wedge pressure (hazard ratio 1.18 [1.09-1.27]), and higher model for end-stage liver disease excluding international normalized ratio score (hazard ratio 1.07, [1.03-1.14]), were associated with death/transplant.

CONCLUSIONS

About 14 % of adults with Fontan palliation were middle-aged, and these patients had higher prevalence of cardiovascular comorbidities, hepatorenal dysfunction, and mortality. These data underscore the need for better risk stratification strategies to identify patients at risk for adverse outcomes and allow for early referral for transplant evaluation in this emerging subpopulation.

CLINICAL SUMMARY

The purpose of this study was to describe the clinical characteristics (comorbidities and end-organ dysfunction) and outcomes (death/transplant) in middle-aged patients with Fontan palliation. Of 455 patients (median age 26 years), 63 (14 %) were middle-aged adults while 392 (86 %) were young adults. Compared to the young adult group, the middle-aged group had a higher prevalence of atrial arrhythmias, greater neurohormonal activation, worse hepatorenal function, and higher risk of death/transplant. The correlates of death/transplant were higher pulmonary artery wedge pressure and hepatorenal dysfunction. These data underscore the need for better risk stratification in this emerging population.

摘要

背景

中年 Fontan 患者在当代研究中代表性不足。本研究旨在描述 Fontan 姑息治疗中年患者的临床特征和结局。

方法

所有接受 Fontan 姑息治疗的成年人分为“中年”组(基线时年龄>40 岁)和“青年”组。评估了多个领域的临床特征(房性心律失常、心力衰竭和肝肾功能)。临床结局评估为死亡/心脏移植的复合结局。

结果

455 名成年人(中位年龄 26 岁)中,63 名(14%)为中年成年人,392 名(86%)为青年成年人。与青年组相比,中年组房性心律失常发生率较高,神经激素激活更严重,肝肾功能更差。63 名中年患者中,26 名(41%)患者死亡,4 名(6%)患者接受心脏移植。中年组 5 年累积死亡/移植发生率(45%比 21%,p<0.001)和 10 年累积死亡/移植发生率(64%比 29%,p<0.001)均高于青年组。较高的肺动脉楔压(风险比 1.18[1.09-1.27])和较高的不包括国际标准化比值的终末期肝病模型评分(风险比 1.07[1.03-1.14])与死亡/移植相关。

结论

约 14%的 Fontan 姑息治疗成年人是中年人,这些患者心血管合并症、肝肾功能障碍和死亡率较高。这些数据强调需要更好的风险分层策略来识别有不良结局风险的患者,并允许在这一新兴亚群中尽早转介进行移植评估。

临床总结

本研究旨在描述 Fontan 姑息治疗中年患者的临床特征(合并症和终末器官功能障碍)和结局(死亡/移植)。455 名患者(中位年龄 26 岁)中,63 名(14%)为中年成年人,392 名(86%)为青年成年人。与青年组相比,中年组房性心律失常发生率较高,神经激素激活更严重,肝肾功能更差,死亡/移植风险更高。死亡/移植的相关因素是肺动脉楔压升高和肝肾功能障碍。这些数据强调了在这一新兴人群中需要更好的风险分层。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验